| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI170362 | Long-acting injectable tacrolimus for chronic immunosuppression | 000 | 2 | NIH | 10/22/2024 | $0 |
| | 2025 | 2022 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44DA053073 | Longer-acting intravaginal formulation of buprenorphine | 000 | 3 | NIH | 12/24/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,025,000 ) |
| | 2024 | 2024 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI136201 | IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes | 000 | 5 | NIH | 7/24/2024 | $1,025,000 |
| | 2024 | 2023 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI170362 | Long-acting injectable tacrolimus for chronic immunosuppression | 000 | 2 | NIH | 5/21/2024 | $0 |
| | 2024 | 2022 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R33AI136008 | IND-enabling preclinical development of a multipurpose intravaginal ring for the prevention of Herpes, HIV and unintended pregnancy | 000 | 5 | NIH | 1/23/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $2,048,600 ) |
| | 2023 | 2023 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI170362 | Long-acting injectable tacrolimus for chronic immunosuppression | 000 | 2 | NIH | 6/22/2023 | $1,023,600 |
| | 2023 | 2023 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI136201 | IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes | 001 | 4 | NIH | 9/14/2023 | $1,025,000 |
| | 2023 | 2020 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI136201 | IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes | 000 | 3 | NIH | 10/17/2022 | $0 |
| | 2023 | 2020 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI124815 | IND-enabling preclinical development of a system for the multipurpose prevention of HIV and unintended pregnancy | 000 | 3 | NIH | 7/26/2023 | $0 |
| | 2023 | 2020 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44DA053073 | Longer-acting intravaginal formulation of buprenorphine | 000 | 1 | NIH | 11/13/2022 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $2,331,349 ) |
| | 2022 | 2022 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI170362 | Long-acting injectable tacrolimus for chronic immunosuppression | 000 | 1 | NIH | 7/8/2022 | $1,024,014 |
| | 2022 | 2022 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R33AI136008 | IND-enabling preclinical development of a multipurpose intravaginal ring for the prevention of Herpes, HIV and unintended pregnancy | 000 | 5 | NIH | 4/14/2022 | $462,000 |
| | 2022 | 2022 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44DA053073 | Longer-acting intravaginal formulation of buprenorphine | 001 | 3 | NIH | 8/17/2022 | $845,335 |
| | 2022 | 2021 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44DA053073 | Longer-acting intravaginal formulation of buprenorphine | 000 | 2 | NIH | 11/16/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $1,360,885 ) |
| | 2021 | 2021 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44DA053073 | Longer-acting intravaginal formulation of buprenorphine | 000 | 1 | NIH | 4/16/2021 | $54,916 |
| | 2021 | 2021 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44DA053073 | Longer-acting intravaginal formulation of buprenorphine | 001 | 2 | NIH | 8/20/2021 | $845,335 |
| | 2021 | 2021 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R33AI136008 | IND-enabling preclinical development of a multipurpose intravaginal ring for the prevention of Herpes, HIV and unintended pregnancy | 000 | 4 | NIH | 3/25/2021 | $460,634 |
| | 2021 | 2019 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R61AI136008 | IND-enabling preclinical development of a multipurpose intravaginal ring for the prevention of Herpes, HIV and unintended pregnancy | 000 | 2 | NIH | 6/3/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,715,239 ) |
| | 2020 | 2020 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI124815 | IND-enabling preclinical development of a system for the multipurpose prevention of HIV and unintended pregnancy | 000 | 3 | NIH | 6/1/2020 | $999,998 |
| | 2020 | 2020 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R33AI136008 | IND-enabling preclinical development of a multipurpose intravaginal ring for the prevention of Herpes, HIV and unintended pregnancy | 000 | 3 | NIH | 4/17/2020 | $461,550 |
| | 2020 | 2020 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44DA053073 | Longer-acting intravaginal formulation of buprenorphine | 000 | 1 | NIH | 9/21/2020 | $253,692 |
| | 2020 | 2020 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44AI136201 | IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes | 000 | 3 | NIH | 2/28/2020 | $1,000,000 |
| | 2020 | 2018 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R43AI136201 | Preclinical development of an intravaginal ring for the sustained release of Pritelivir for the treatment and prophylaxis of Genital Herpes in women | 000 | 1 | NIH | 10/28/2019 | $0 |
| | 2020 | 2017 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R43HD090870 | Preclinical development of an intravaginal ring for the sustained-release of octreotide for the treatment of acromegaly. | 000 | 1 | NIH | 12/19/2019 | -$1 |
| | 2020 | 2017 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | U44AI069674 | Clinical Safety and Pharmacokinetics of Sustained Release Depot Tacrolimus | 000 | 5 | NIH | 3/18/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $2,321,077 ) |
| | 2019 | 2019 | AURITEC PHARMACEUTICALS INC | 3200 SANTA MONICA BLVD STE 201 | SANTA MONICA | CA | 90404-2639 | LOS ANGELES | USA | R44AI124815 | IND-enabling preclinical development of a system for the multipurpose prevention of HIV and unintended pregnancy | 001 | 2 | NIH | 8/21/2019 | $1,929 |
| | 2019 | 2019 | AURITEC PHARMACEUTICALS INC | 3200 SANTA MONICA BLVD STE 201 | SANTA MONICA | CA | 90404-2639 | LOS ANGELES | USA | R44AI136201 | IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes | 000 | 2 | NIH | 4/3/2019 | $860,561 |
| | 2019 | 2019 | AURITEC PHARMACEUTICALS INC | 3200 SANTA MONICA BLVD STE 201 | SANTA MONICA | CA | 90404-2639 | LOS ANGELES | USA | R44AI124815 | IND-enabling preclinical development of a system for the multipurpose prevention of HIV and unintended pregnancy | 000 | 2 | NIH | 7/22/2019 | $998,069 |
| | 2019 | 2019 | AURITEC PHARMACEUTICALS INC | 3200 SANTA MONICA BLVD STE 201 | SANTA MONICA | CA | 90404-2639 | LOS ANGELES | USA | R61AI136008 | IND-enabling preclinical development of a multipurpose intravaginal ring for the prevention of Herpes, HIV and unintended pregnancy | 000 | 2 | NIH | 3/10/2019 | $433,812 |
| | 2019 | 2018 | AURITEC PHARMACEUTICALS INC | 3200 SANTA MONICA BLVD STE 201 | SANTA MONICA | CA | 90404-2639 | LOS ANGELES | USA | R43AI136201 | Preclinical development of an intravaginal ring for the sustained release of Pritelivir for the treatment and prophylaxis of Genital Herpes in women | 001 | 1 | NIH | 6/28/2019 | $26,706 |
| | 2019 | 2018 | AURITEC PHARMACEUTICALS INC | 3200 SANTA MONICA BLVD STE 201 | SANTA MONICA | CA | 90404-2639 | LOS ANGELES | USA | R43AI136201 | Preclinical development of an intravaginal ring for the sustained release of Pritelivir for the treatment and prophylaxis of Genital Herpes in women | 000 | 1 | NIH | 3/28/2019 | $0 |
| | 2019 | 2016 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R43AI124815 | Preclinical development of a multipurpose intravaginal ring for the prevention of HIV and unintended pregnancy | 000 | 1 | NIH | 11/1/2018 | $0 |
| | 2019 | 2016 | AURITEC PHARMACEUTICALS, INC. | 2285 E FOOTHILL BLVD | PASADENA | CA | 91107-3658 | LOS ANGELES | USA | R44MH110161 | Automation of GMP manufacturing of HIV microbicide rings | 000 | 6 | NIH | 11/15/2018 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $659,446 ) |
| | 2018 | 2018 | AURITEC PHARMACEUTICALS INC | 3200 SANTA MONICA BLVD STE 201 | SANTA MONICA | CA | 90404-2639 | LOS ANGELES | USA | R43AI136201 | Preclinical development of an intravaginal ring for the sustained release of Pritelivir for the treatment and prophylaxis of Genital Herpes in women | 000 | 1 | NIH | 1/25/2018 | $224,484 |
| | 2018 | 2018 | AURITEC PHARMACEUTICALS INC | 3200 SANTA MONICA BLVD STE 201 | SANTA MONICA | CA | 90404-2639 | LOS ANGELES | USA | R61AI136008 | IND-enabling preclinical development of a multipurpose intravaginal ring for the prevention of Herpes, HIV and unintended pregnancy | 000 | 1 | NIH | 2/27/2018 | $434,962 |
| | 2018 | 2016 | AURITEC PHARMACEUTICALS INC | 3200 SANTA MONICA BLVD STE 201 | SANTA MONICA | CA | 90404-2639 | LOS ANGELES | USA | R44HD075636 | Clinical safety and pharmacokinetic studies of intravaginal rings releasing multiple antiretrovirals | 000 | 3 | NIH | 7/30/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $936,025 ) |
| | 2017 | 2017 | AURITEC PHARMACEUTICALS INC | 3200 SANTA MONICA BLVD STE 201 | SANTA MONICA | CA | 90404-2639 | LOS ANGELES | USA | R43HD090870 | Preclinical development of an intravaginal ring for the sustained-release of octreotide for the treatment of acromegaly. | 000 | 1 | NIH | 9/1/2017 | $224,881 |
| | 2017 | 2017 | AURITEC PHARMACEUTICALS INC | 3200 SANTA MONICA BLVD STE 201 | SANTA MONICA | CA | 90404-2639 | LOS ANGELES | USA | U44AI069674 | Clinical Safety and Pharmacokinetics of Sustained Release Depot Tacrolimus | 001 | 5 | NIH | 7/25/2017 | $766,264 |
| | 2017 | 2016 | AURITEC PHARMACEUTICALS INC | 3200 SANTA MONICA BLVD STE 201 | SANTA MONICA | CA | 90404-2639 | LOS ANGELES | USA | U44AI069674 | Clinical Safety and Pharmacokinetics of Sustained Release Depot Tacrolimus | 000 | 4 | NIH | 7/24/2017 | -$55,120 |
| | 2017 | 2013 | AURITEC PHARMACEUTICALS INC | 3200 SANTA MONICA BLVD STE 201 | SANTA MONICA | CA | 90404-2639 | LOS ANGELES | USA | U01FD004927 | An IVIVC system to facilitate the development of a generic Vitrasert | 000 | 1 | FDA | 6/27/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $2,589,591 ) (Continued on the next page) |
|
